公开(公告)号：US20180142349A1

公开(公告)日：2018-05-24

申请号：US15576215

申请日：2016-05-20

Applicant: Universität ULM

Inventor： Anton Reiser ,  Manfred Madel ,  Florian Huber ,  Klaus Thonke

IPC: C23C16/40

CPC classification number: C23C16/407 ,  C30B25/00 ,  C30B29/16

Abstract: A method for depositing zinc oxide on a substrate is disclosed. In an embodiment, the method includes reducing, in a first stage, a source material comprising zinc oxide to zinc which is gaseous at reaction conditions by contacting the source material with a gaseous reducing agent, transporting, in a second stage locally separate from the first stage, the gaseous zinc to the substrate, wherein the gaseous zinc is converted to zinc oxide by adding an oxidizing agent; and depositing the zinc oxide on a surface of the substrate, wherein the gaseous reducing agent is methane or a thermal decomposition product of at least one precursor, which is thermally decomposed at the reaction conditions of the first stage so that methane, methyl radicals and/or acetone is released.

公开(公告)号：US09034599B2

公开(公告)日：2015-05-19

申请号：US14164903

申请日：2014-01-27

Applicant: Universität Ulm

Inventor： Jörg Wiedenmann ,  Simone Kredel ,  Franz Oswald ,  Gerd Ulrich Nienhaus

IPC: C12P21/06 ,  C12N15/00 ,  C12N5/00 ,  C12N5/07 ,  C12N1/20 ,  C12N1/00 ,  C07K14/435 ,  G01N33/58

CPC classification number: C07K14/43504 ,  C07K14/43595 ,  G01N33/582

Abstract: DNA encoding a monomeric variant of red fluorescent protein eqFP611 comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5. DNA comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.

Abstract translation: 编码红色荧光蛋白eqFP611的单体变体的DNA，其包含选自SEQ ID No.1，SEQ ID No.3和SEQ ID No.5的氨基酸序列。包含选自下组的核苷酸序列的DNA： SEQ ID No.2，SEQ ID No.4和SEQ ID No.6。

公开(公告)号：US20210355178A1

公开(公告)日：2021-11-18

申请号：US17255228

申请日：2019-06-21

Applicant: Universität Ulm

Inventor： Christoph Schmidt ,  Markus Huber-Lang

IPC: C07K14/47

Abstract: The present invention relates to a multi-module polypeptide comprising (i) an Fc receptor binding module; (ii) a first complement control protein repeat (CCP) module; and (iii) a second CCP module binding to at least one host cell surface marker, to complement factor C3b, to complement factor C4b, to a degradation product of complement factor C3b, and/or to a degradation product of complement factor C4b; wherein said second CCP module is C-terminal of said Fc receptor binding module and of said first CCP module. The present invention also relates to a polynucleotide encoding said multi-module polypeptide, and to said multi-module polypeptide for use in medicine, in particular for use in treating and/or preventing inappropriate complement activation and/or a disease having inappropriate complement activation as a symptom. Moreover, the present invention relates to an in vitro method for preventing or reducing the degree of complement activation comprising applying a multi-module polypeptide to a reaction mixture, a tissue, and/or an organ comprising complement factors, thereby preventing or reducing the degree of complement activation in said reaction mixture, tissue, and/or organ.

公开(公告)号：US20210122771A1

公开(公告)日：2021-04-29

申请号：US17255963

申请日：2019-06-28

Applicant: The Regents of the University of California ,  UNIVERSITÄT DUISBURG-ESSEN ,  UNIVERSITÄT ULM

Inventor： Gal Bitan ,  Thomas Schrader ,  Jan Münch ,  Christian Heid ,  Andrea Sowislok ,  Annika Röcker ,  Danielle Bouquio ,  Ravinder Malik

IPC: C07F9/12 ,  A61P25/28 ,  A61P31/18 ,  A61P31/14

Abstract: In various embodiments new molecular tweezers compounds are provided. The compounds described herein (e.g., molecular tweezers) are believed to be useful for inhibiting protein aggregation (or disaggregating aggregated proteins). In certain embodiments the compounds described herein (e.g., molecular tweezers) are believed to be useful in the treatment of pathologies characterized by protein aggregation (e.g., amyloidopathies), and/or in the treatment of brain or spinal cord damage associated with acute trauma, stroke, and the like, and/or in the treatment of lysosomal storage diseases, and/or in the treatment of lipofuscin-related disorders, and in various viral infections.

公开(公告)号：US20170348727A1

公开(公告)日：2017-12-07

申请号：US15537545

申请日：2015-12-14

Applicant: UNIVERSITÄT ULM

Inventor： Steffen STREHLE ,  Daniel Markus ROSSKOPF ,  Andreas Magnus PROBST

IPC: B05D1/28 ,  H05K3/12 ,  B81C1/00 ,  H05K1/03 ,  H05K1/09

CPC classification number: B05D1/28 ,  B81C1/00373 ,  B81C2201/0185 ,  B81C2201/0187 ,  B82B3/0066 ,  H05K1/0306 ,  H05K1/09 ,  H05K3/102 ,  H05K3/1275 ,  H05K2201/026 ,  H05K2201/09036 ,  H05K2201/09045 ,  H05K2203/0108 ,  H05K2203/0271 ,  H05K2203/0528

Abstract: The invention relates to a method for producing a substrate structured by nanowires, characterized in that no lubricant and no lithographic resist mask is used in the method, and only by moving a donor substrate having nanowires relative to a substrate and by locally tribological properties on the surface of the substrate, a specified number of nanowires is deposited selectively at locally defined points of the substrate. The invention further relates to a substrate that can be produced using the method according to the invention, and which selectively contains a specified number of nanowires on a surface at locally defined points. The invention further relates to the use of the substrate according to the invention in microelectronics, microsystems technology, and/or micro-sensor systems.